1. Home
  2. ENOV vs COLL Comparison

ENOV vs COLL Comparison

Compare ENOV & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enovis Corporation

ENOV

Enovis Corporation

N/A

Current Price

$22.60

Market Cap

1.4B

Sector

Industrials

ML Signal

N/A

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

N/A

Current Price

$33.74

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENOV
COLL
Founded
1995
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Fluid Controls
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2008
2015

Fundamental Metrics

Financial Performance
Metric
ENOV
COLL
Price
$22.60
$33.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
$47.38
$51.40
AVG Volume (30 Days)
694.5K
443.1K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.73
Revenue
N/A
$780,567,000.00
Revenue This Year
$6.36
$8.01
Revenue Next Year
$5.31
N/A
P/E Ratio
N/A
$19.51
Revenue Growth
N/A
23.62
52 Week Low
$21.00
$26.72
52 Week High
$36.82
$50.79

Technical Indicators

Market Signals
Indicator
ENOV
COLL
Relative Strength Index (RSI) 43.12 49.72
Support Level $21.52 $31.18
Resistance Level $23.57 $36.22
Average True Range (ATR) 1.25 1.31
MACD -0.26 0.22
Stochastic Oscillator 8.16 54.08

Price Performance

Historical Comparison
ENOV
COLL

About ENOV Enovis Corporation

Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: